Investment Rating - The report suggests a positive investment outlook for the beauty and personal care sector, recommending a "buy" rating for high-growth companies with strong brand power and innovative product offerings [2][3]. Core Insights - The beauty and personal care sector is experiencing a slow recovery, with significant differentiation among sub-sectors. Personal care products and innovative channels continue to perform strongly, while the cosmetics sector shows signs of slowing growth due to domestic brand competition [1][2][3]. - For 2026, the overall beauty and personal care market is expected to remain stable, but further differentiation among companies is anticipated. The report emphasizes the importance of selecting high-growth targets with product and channel innovations [2][3]. Summary by Sections Overall Market Performance - In the first three quarters of 2025, the beauty and personal care sector saw revenues and net profits increase by 2.7% and 4.9% respectively, with personal care outperforming cosmetics and medical aesthetics [12][31]. - The cosmetics sector experienced a slight decline in revenue, with a 0.4% decrease year-on-year, while net profit fell by 2.3% [31][33]. Personal Care Sector - The personal care segment achieved revenues of 52 billion yuan and net profits of 5 billion yuan, reflecting a year-on-year increase of 33.7% and 5.7% respectively. The third quarter alone saw a revenue increase of 41.1% [12][16]. - Companies like Ruoyuchen reported impressive growth, with a 123% increase in revenue and a 73% increase in net profit in the third quarter [12][28]. Cosmetics Sector - The cosmetics sector's revenue for the first three quarters was 308 billion yuan, with a net profit of 30 billion yuan, showing a decline of 0.4% and 2.3% respectively. The third quarter saw a revenue drop of 0.5% but a significant profit increase of 50.8% [12][31]. - The report highlights the importance of individual company strategies and product life cycles in determining performance within the cosmetics sector [13][48]. Medical Aesthetics Sector - The medical aesthetics segment reported revenues of 75 billion yuan and net profits of 27 billion yuan, with a slight revenue decline of 0.7% but a profit increase of 14.5% year-on-year [12][52]. - The third quarter saw a revenue increase of 1.8% and a remarkable profit growth of 96.6%, although underlying performance was affected by increased competition and integration challenges [52][56]. Investment Recommendations - The report recommends focusing on high-growth companies with strong brand power, such as Ruoyuchen, Shangmei, and Maogeping, as well as companies with stable fundamentals and potential for marginal improvement like Dengkang Oral and Shanghai Jahwa [2][3]. - It also suggests monitoring companies that are expected to reach a turning point, such as Runben and Jinjian Biological, which may present investment opportunities [2][3].

Group 1 - The report highlights the significant achievements in the recent China-US trade talks, with the US agreeing to suspend certain tariffs on Chinese goods, which may positively impact trade dynamics [7] - The macroeconomic policy emphasizes the importance of expanding domestic demand and improving living standards, as outlined in the "15th Five-Year Plan" [5][6] - The report notes a shift in export growth, with October exports showing a decline of 1.1% year-on-year, influenced by high base effects from the previous year [11][12] Group 2 - The report discusses the rebalancing between technology and cyclical sectors, suggesting that both will play significant roles in the market moving forward [17][20] - It identifies the satellite industry as a strategic investment opportunity, driven by large market potential, strong policy support, and technological advancements [23][24] - The report indicates that the REIT market is showing resilience, with the recent listing of the CITIC Construction Investment Shenyang International Software Park REIT, which is expected to attract investment due to its high dividend yield [65][66]

Investment Rating - The investment rating for the beauty and personal care industry is "Positive" (maintained) [3] Core Viewpoints - The beauty market in China showed steady performance in Q1-Q3 2025, with retail sales of cosmetics growing by 3.9% year-on-year, surpassing the overall retail sales growth of consumer goods at 3.3% [4][5] - The high-end segment is expected to outperform the mass market, with projected CAGR for high-end skincare and makeup at 9.6% and 10.8% respectively from 2023 to 2028, compared to 8.2% and 6.7% for the mass market [6] Summary by Sections Market Performance - In Q1-Q3 2025, the beauty market maintained stable demand, with monthly retail sales growth fluctuating, peaking at 8.6% in September [4][5] - The personal care segment performed well, with revenue reaching 52.3 billion yuan, a year-on-year increase of 33.7% [16] Segment Analysis - Cosmetics segment revenue was 299.9 billion yuan, with a slight increase of 0.02%, while net profit decreased by 2.5% [16] - The medical beauty segment saw revenue of 74.9 billion yuan, a decrease of 0.7%, but net profit increased by 14.5% [16] - The personal care segment's revenue growth was driven by product innovation and expansion, with notable performances from companies like RuBen and RYTHM [16] Brand Competition - The competitive landscape is stable, with domestic brands like Proya and Han Shu gaining market share, particularly in platforms like Tmall and Douyin [11][12] - The report highlights the increasing strength of domestic brands due to their brand power and local advantages [12]

Core Insights - The retail industry is experiencing a shift from value preservation to emotional value, with a focus on high-growth segments for investment opportunities [5][28] - The report maintains a positive outlook on the retail sector, emphasizing the importance of consumer insights and differentiated product offerings [5][28] Retail Market Overview - The retail index reported a slight increase of 0.31% during the week of November 3 to November 7, 2025, underperforming the Shanghai Composite Index, which rose by 1.08% [7][16] - Year-to-date, the retail index has increased by 4.20%, lagging behind the Shanghai Composite Index's 19.27% growth [16][20] Investment Strategy for 2026 - The investment strategy highlights four main themes: 1. **Gold and Jewelry**: Focus on high-end and fashionable gold segments, with recommendations for brands like Lao Pu Gold and Chao Hong Ji [5][48] 2. **Retail E-commerce**: Emphasize the transformation of offline retail to enhance service and experience, with key players like Yonghui Supermarket and Ai Ying Shi [5][48] 3. **Cosmetics**: Target domestic brands that capture emotional value and innovate on safety ingredients, recommending brands like Juzi Biological and Pechoin [5][49] 4. **Medical Aesthetics**: Focus on differentiated product manufacturers and expanding medical institutions, with recommendations for brands like Ai Mei Ke and Ke Di-B [5][49] Sector Performance - The jewelry sector is undergoing significant changes due to rising gold prices and a decline in traditional wedding markets, leading to the emergence of brands with strong consumer insights [5][29] - The cosmetics sector is seeing a rise in domestic brands leveraging cultural roots and emotional value to capture market share [5][41] Company-Specific Insights - **Chao Hong Ji**: Reported a revenue increase of 28.4% year-on-year for the first three quarters of 2025, with a notable performance in Q3 [54] - **Yonghui Supermarket**: Experienced a revenue decline of 22.2% year-on-year for the first three quarters of 2025, but is undergoing significant transformation [50] - **Juzi Biological**: Achieved a revenue growth of 21.7% year-on-year for the first half of 2025, focusing on collagen products [50]

Market Overview - The personal care products sector increased by 0.76% on November 7, with Yanjiang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Yanjiang Co., Ltd. (300658) closed at 9.15, up 2.35% with a trading volume of 122,400 shares and a turnover of 112 million yuan [1] - Beijia Clean (603059) closed at 31.80, up 2.09% with a trading volume of 31,500 shares and a turnover of 99.4 million yuan [1] - Stable Medical (300888) closed at 41.00, up 1.91% with a trading volume of 77,500 shares and a turnover of 318 million yuan [1] - Other notable stocks include Jeya Co., Ltd. (301108) up 0.91% and Baiya Co., Ltd. (003006) up 0.58% [1] Fund Flow Analysis - The personal care products sector experienced a net outflow of 12.73 million yuan from institutional investors, while retail investors saw a net inflow of 5.30 million yuan [2] - The overall fund flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Fund Flow - Yiyi Co., Ltd. (001206) had a net inflow of 9.33 million yuan from institutional investors but a net outflow of 18.01 million yuan from retail investors [3] - Yanjiang Co., Ltd. (300658) saw a net inflow of 5.49 million yuan from institutional investors but a net outflow of 7.83 million yuan from retail investors [3] - Stable Medical (300888) had a net inflow of 2.14 million yuan from institutional investors and a net outflow of 15.55 million yuan from retail investors [3]

Core Viewpoint - The personal care products sector experienced a decline of 0.3% on November 6, with Runben Co., Ltd. leading the drop. Meanwhile, the Shanghai Composite Index rose by 0.97% to close at 4007.76, and the Shenzhen Component Index increased by 1.73% to 13452.42 [1]. Group 1: Market Performance - The personal care products sector saw a mixed performance among individual stocks, with notable gainers including Beijiajie (+1.53%) and Liangmianjin (+1.08%), while Runben Co., Ltd. led the decline at -1.86% [1][2]. - The trading volume for Beijiajie was 21,300 hands, with a transaction value of approximately 65.74 million yuan, while Runben Co., Ltd. had a trading volume of 41,700 hands and a transaction value of about 108 million yuan [1][2]. Group 2: Capital Flow - The personal care products sector experienced a net outflow of 23.85 million yuan from institutional investors, while retail investors saw a net inflow of 15.48 million yuan [2]. - Among individual stocks, Liangmianjin attracted a net inflow of 11.18 million yuan from institutional investors, while Runben Co., Ltd. faced a net outflow of 1.36 million yuan [3].

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Runben Biotechnology Co., Ltd. on November 5, 2025, with no resolutions being rejected [1][2]. - The meeting was convened by the board of directors and chaired by Mr. Zhao Guiqin, with a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][3]. - All six current directors attended the meeting, along with the board secretary [3]. Group 2 - One of the key resolutions passed was the reappointment of the accounting firm, which was approved by the shareholders [4]. - The meeting was witnessed by Guangdong Guangxin Junda Law Firm, with lawyers Zhang Wei and Ma Xiaoxi confirming the legality and validity of the meeting's procedures and resolutions [5].

广东广信君达律师事务所 关于润本生物技术股份有限公司 2025 年第三次临时股东会的法律意见书 致：润本生物技术股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托，指派张伟、马小希律师（以下简称"本律师"）出席了公司于 2025 年 11 月 5 日（星期三）下午 15:30 在广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼公司 会议室召开的 2025 年第三次临时股东会（以下简称"本次股东会"），并依据《中华人民共 和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》、《上海证券交易所股 票上市规则》等中国现行法律、法规和其它规范性法律文件（以下合称"法律法规"）以及《润 本生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，就本次股东会的召集 和召开程序、出席会议人员的资格和召集人资格、表决程序和表决结果等相关事宜出具法律意 见。 为出具本法律意见书，本律师听取了公司就有关事实的陈述和说明，审查了公司提供的相 关文件，包括但不限于： 1. 公司章程； 2. 第二届董事会第十次会议决议公告； 3. 公司于 2025 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-047 润本生物技术股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 5 日 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，公司董事长赵贵钦先生主持。本次股东会采 用现场投票和网络投票相结合的方式召开并表决，会议的召开及表决符合《公司 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：《关于续聘会计师事务所的议案》 审议结果：通过 表决情况： (二)股东会召开的地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信大 厦 40 楼润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有 ...

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].